Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Barrans, S. Crouch, Alex Smith, K. Turner, R. Owen, R. Patmore, E. Roman, A. Jack (2010)Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 20
C. Chang, C. Chang, Yao Liu, R. Cleveland, S. Perkins (2000)Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas.
American journal of clinical pathology, 113 4
R. Dalla-Favera, M. Bregni, J. Erikson, D. Patterson, R. Gallo, C. Croce (1982)Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.
Proceedings of the National Academy of Sciences of the United States of America, 79 24
Aine McCarthy, J. Marzec, A. Clear, R. Petty, R. Coutinho, J. Matthews, Andrew Wilson, S. Iqbal, M. Calaminici, J. Gribben, L. Jia (2014)Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2
M. Michaelis, F. Selt, F. Rothweiler, N. Löschmann, Benedikt Nüsse, W. Dirks, R. Zehner, J. Cinatl (2014)Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
PLoS ONE, 9
Yuan Cheng, LI Geng, Lijun Zhao, Peng Zuo, Jianliu Wang (2015)Targeting the Mitotic Catastrophe Signaling Pathway in Cancer
Mediators of Inflammation, 2015
Xinbing Sui, R. Chen, Z. Wang, Zehuan Huang, Na Kong, M. Zhang, W. Han, F. Lou, J. Yang, Qiang Zhang, Xian Wang, Chao He, H. Pan (2013)Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
Cell Death & Disease, 4
Tatsuo Hata, T. Furukawa, M. Sunamura, S. Egawa, F. Motoi, Noriyuki Ohmura, Tomotoshi Marumoto, H. Saya, A. Horii (2005)RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.
Cancer research, 65 7
R. Fisher, E. Gaynor, S. Dahlberg, M. Oken, T. Grogan, E. Mize, J. Glick, C. Coltman, T. Miller (1993)Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
The New England journal of medicine, 328 14
K. Pagnano, J. Vassallo, I. Lorand-Metze, F. Costa, S. Saad (2001)p53, Mdm2, and c‐Myc overexpression is associated with a poor prognosis in aggressive non‐Hodgkin's lymphomas
American Journal of Hematology, 67
Kyung-Chae Jeong, Kyung-Ohk Ahn, Chul-hak Yang (2010)Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest.
Molecular bioSystems, 6 8
J. Vose (1998)Current approaches to the management of non-Hodgkin's lymphoma.
Seminars in oncology, 25 4
N. Dubrawsky (1989)Cancer statistics
CA: A Cancer Journal for Clinicians, 39
Charles Lin, Jakob Lovén, P. Rahl, Ronald Paranal, C. Burge, J. Bradner, Tong Lee, R. Young (2012)Transcriptional Amplification in Tumor Cells with Elevated c-Myc
S. Dietrich (2018)Faculty of 1000 evaluation for The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
R. Siegel, K. Miller, A. Jemal (2015)Cancer statistics, 2015
CA: A Cancer Journal for Clinicians, 65
C. Nesbit, J. Tersak, E. Prochownik (1999)MYC oncogenes and human neoplastic disease
C. Love, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, R. Miles, K. Richards, C. Dunphy, W. Choi, G. Srivastava, P. Lugar, D. Rizzieri, A. Lagoo, L. Bernal-Mizrachi, K. Mann, C. Flowers, K. Naresh, A. Evens, A. Chadburn, L. Gordon, M. Czader, J. Gill, E. Hsi, A. Greenough, Andrea Moffitt, M. McKinney, A. Banerjee, V. Grubor, S. Levy, D. Dunson, S. Dave (2012)The genetic landscape of mutations in Burkitt lymphoma
Nature Genetics, 44
N. Johnson, G. Slack, K. Savage, J. Connors, S. Ben-Neriah, S. Rogic, D. Scott, K. Tan, C. Steidl, L. Sehn, W. Chan, J. Iqbal, Paul Meyer, G. Lenz, George Wright, L. Rimsza, C. Valentino, P. Brunhoeber, T. Grogan, R. Braziel, J. Cook, R. Tubbs, D. Weisenburger, E. Campo, A. Rosenwald, G. Ott, J. Delabie, C. Holcroft, E. Jaffe, L. Staudt, R. Gascoyne (2012)Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
Jin-Ping Li, Yinxue Yang, Qilun Liu, S. Pan, Zhi-xu He, Xueji Zhang, Tianxin Yang, Xiao-wu Chen, Dong Wang, J. Qiu, Shufeng Zhou (2015)The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
Drug Design, Development and Therapy, 9
IB Weinstein (2002)Cancer. Addiction to oncogenes—the Achilles heal of cancer
L. Rimsza, M. LeBlanc, J. Unger, T. Miller, T. Grogan, D. Persky, R. Martel, C. Sabalos, B. Seligmann, R. Braziel, E. Campo, A. Rosenwald, J. Connors, L. Sehn, N. Johnson, R. Gascoyne (2008)Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
Blood, 112 8
James Duncan, Martin Whittle, K. Nakamura, A. Abell, Alicia Midland, J. Zawistowski, N. Johnson, D. Granger, N. Jordan, David Darr, Jerry Usary, Pei-Fen Kuan, D. Smalley, Ben Major, Xiaping He, K. Hoadley, Bing-sen Zhou, N. Sharpless, C. Perou, William Kim, S. Gomez, Xin Chen, Jian Jin, S. Frye, H. Earp, L. Graves, G. Johnson (2012)Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
S. Nair, S. Burley (2003)X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors
D. Mahadevan, A. Stejskal, Laurence Cooke, Ann Manziello, C. Morales, D. Persky, R. Fisher, T. Miller, W. Qi (2012)Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
Clinical Cancer Research, 18
J. Hollander, Sara Rimpi, J. Doherty, M. Rudelius, A. Buck, Alexander Hoellein, M. Kremer, N. Graf, M. Scheerer, Mark Hall, A. Goga, N. Bubnoff, J. Duyster, C. Peschel, J. Cleveland, J. Nilsson, U. Keller (2010)Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
Blood, 116 9
G. Görgün, E. Calabrese, T. Hideshima, J. Ecsedy, G. Perrone, M. Mani, H. Ikeda, G. Bianchi, Yiguo Hu, D. Cirstea, L. Santo, Y. Tai, Sabikun Nahar, Mei Zheng, Madhavi Bandi, Ruben Carrasco, N. Raje, N. Munshi, P. Richardson, K. Anderson (2009)A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Blood, 115 25
Dragan Marinkovic, Tatjana Marinkovic, B. Mahr, J. Hess, T. Wirth (2004)Reversible lymphomagenesis in conditionally c‐MYC expressing mice
International Journal of Cancer, 110
D. Dauch, Ramona Rudalska, G. Cossa, J. Nault, T. Kang, T. Wuestefeld, Anja Hohmeyer, S. Imbeaud, T. Yevsa, L. Hoenicke, Tatu Pantsar, P. Bozko, N. Malek, T. Longerich, S. Laufer, A. Poso, J. Zucman‐Rossi, M. Eilers, L. Zender (2016)A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
Nature Medicine, 22
Z. Nie, Gangqing Hu, Gang Wei, Kairong Cui, Arito Yamane, W. Resch, Ruoning Wang, D. Green, L. Tessarollo, R. Casellas, K. Zhao, David Levens (2012)c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells
Alejandra Carvajal-Cuenca, S. Pileri, E. Campo (2013)The World Health Organization Classification of Lymphoid Neoplasms
A. Sáez, M. Artiga, Cristina Romero, Sandra Rodríguez, J. Cigudosa, A. Pérez‐Rosado, I. Fernández, M. Sánchez-Beato, E. Sánchez, M. Mollejo, M. Piris (2003)Development of a Real-Time Reverse Transcription Polymerase Chain Reaction Assay for c-myc Expression That Allows the Identification of a Subset of c-myc+ Diffuse Large B-Cell Lymphoma
Laboratory Investigation, 83
D. Felsher, J. Bishop (1999)Transient excess of MYC activity can elicit genomic instability and tumorigenesis.
Proceedings of the National Academy of Sciences of the United States of America, 96 7
K. Savage, N. Johnson, S. Ben-Neriah, J. Connors, L. Sehn, Pedro Farinha, D. Horsman, R. Gascoyne (2009)MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Blood, 114 17
M. Hummel, S. Bentink, Hilmar Berger, W. Klapper, S. Wessendorf, T. Barth, H. Bernd, S. Cogliatti, J. Dierlamm, A. Feller, M. Hansmann, E. Haralambieva, L. Harder, D. Hasenclever, M. Kühn, D. Lenze, P. Lichter, J. Martín-Subero, P. Möller, H. Müller-hermelink, G. Ott, R. Parwaresch, C. Pott, A. Rosenwald, M. Rosolowski, C. Schwaenen, Benjamin Stürzenhofecker, M. Szczepanowski, H. Trautmann, H. Wacker, R. Spang, M. Loeffler, L. Trümper, H. Stein, R. Siebert (2006)A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
The New England journal of medicine, 354 23
M. Carducci, M. Shaheen, B. Markman, S. Hurvitz, D. Mahadevan, D. Kotasek, Oscar Goodman, E. Rasmussen, V. Chow, Gloria Juan, G. Friberg, E. Gamelin, F. Vogl, J. Desai (2018)A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Investigational New Drugs, 36
Assila Belounis, C. Nyalendo, Roxane Gall, T. Imbriglio, Mohamed Mahma, P. Teira, M. Beaunoyer, Sonia Cournoyer, E. Haddad, G. Vassal, H. Sartelet (2016)Autophagy is associated with chemoresistance in neuroblastoma
BMC Cancer, 16
C. Topham, A. Tighe, P. Ly, A. Bennett, Olivia Sloss, Louisa Nelson, R. Ridgway, D. Huels, Samantha Littler, Claudia Schandl, Ying Sun, Beatrice Bechi, D. Procter, O. Sansom, D. Cleveland, Stephen Taylor (2015)MYC Is a Major Determinant of Mitotic Cell Fate
Cancer Cell, 28
Vikas Sehdev, D. Peng, M. Soutto, M. Washington, Frank Revetta, J. Ecsedy, A. Zaika, T. Rau, R. Schneider-Stock, A. Belkhiri, W. El-Rifai (2012)The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
Molecular Cancer Therapeutics, 11
K. Vousden, Tim Crook, Paul Farrell (1993)Biological activities of p53 mutants in Burkitt's lymphoma cells.
The Journal of general virology, 74 ( Pt 5)
H. Poirel, H. Poirel, M. Cairo, N. Heerema, J. Swansbury, A. Aupérin, E. Launay, W. Sanger, P. Talley, S. Perkins, M. Raphael, M. Raphael, K. McCarthy, R. Sposto, M. Gerrard, A. Bernheim, C. Patte (2008)Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study
D. Felsher, J. Bishop (1999)Reversible tumorigenesis by MYC in hematopoietic lineages.
Molecular cell, 4 2
S. Giuriato, S. Ryeom, A. Fan, P. Bachireddy, R. Lynch, M. Rioth, Jan Riggelen, Andrew Kopelman, E. Passegué, F. Tang, J. Folkman, D. Felsher (2006)Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch
Proceedings of the National Academy of Sciences, 103
SH Swerdlow, E Campo, SA Pileri (2016)The 2016 revision of the World Health Organization classification of lymphoid neoplasms
A. Duthu, B. Debuire, J. Romano, J. Ehrhart, M. Fiscella, E. May, E. Appella, P. May (1992)p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas.
Oncogene, 7 11
W. Cuccuini, J. Brière, N. Mounier, H. Voelker, A. Rosenwald, C. Sundstrom, S. Cogliatti, E. Hirchaud, L. Ysebaert, D. Bron, J. Soulier, P. Gaulard, R. Houlgatte, C. Gisselbrecht, C. Thieblemont (2012)MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
J. Zawistowski, Samantha Bevill, D. Goulet, T. Stuhlmiller, Adriana Beltran, J. Olivares-Quintero, Darshan Singh, N. Sciaky, Joel Parker, N. Rashid, Xin Chen, James Duncan, Martin Whittle, Steven Angus, S. Velarde, B. Golitz, Xiaping He, Charlene Santos, David Darr, K. Gallagher, Lee Graves, C. Perou, L. Carey, H. Earp, G. Johnson (2017)Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Cancer discovery, 7 3
E. Prochownik, P. Vogt (2010)Therapeutic Targeting of Myc.
Genes & cancer, 1 6
R. Diaz, B. Golbourn, C. Faria, D. Picard, D. Shih, Denis Raynaud, Michael Leadly, Danielle Mackenzie, Melissa Bryant, Matthew Bebenek, Christian Smith, Michael Taylor, A. Huang, J. Rutka (2014)Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma
K. Degenhardt, R. Mathew, Brian Beaudoin, K. Bray, Diana Anderson, Guanghua Chen, Chandreyee Mukherjee, Yufang Shi, C. Gélinas, Yongjun Fan, D. Nelson, Shengkan Jin, E. White (2006)Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis.
Cancer cell, 10 1
Marc Payton, T. Bush, Grace Chung, B. Ziegler, Patrick Eden, P. McElroy, Sandra Ross, V. Cee, H. Deak, Brian Hodous, H. Nguyen, P. Olivieri, Karina Romero, L. Schenkel, A. Bak, Mary Stanton, I. Dussault, V. Patel, Stephanie Geuns-Meyer, R. Radinsky, R. Kendall (2010)Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Cancer research, 70 23
I. Weinstein (2002)Addiction to Oncogenes--the Achilles Heal of Cancer
W. Klapper, H. Stoecklein, H. Stoecklein, S. Zeynalova, G. Ott, F. Kosari, F. Kosari, A. Rosenwald, M. Loeffler, L. Trümper, M. Pfreundschuh, R. Siebert (2008)Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Background Aberrant Myc expression plays a critical role in various tumors, including non-Hodgkin lymphoma (NHL). Myc-positive lymphoma is clinically aggressive, more resistant to chemotherapy, and associated with high mortality. Objective The current study aimed to show inhibition of aurora A kinase (AURKA) may overcome resistance to chemo- therapy and improve outcomes in Myc-overexpressing lymphoma. Methods Myc-overexpressing lymphoma cell lines were evaluated by trypan blue, annexin V/propidium iodide staining, and western blotting for cytotoxicity, cell cycle, apoptosis, and Myc-associated protein expression, respectively, in the presence of cyclophosphamide with or without MLN8237, an AURKA inhibitor. Immunofluorescence for apoptosis-inducing factor (AIF) and acridine orange staining were used to analyze levels of autophagy. EµMyc genetically modified mouse model and xenograft models bearing Myc-overexpressing lymphoma cells were used to determine the efficacy of cyclophosphamide, MLN8237, or the combination in chemosensitive and chemoresistant tumors. Results In our in vitro experiments using chemoresistant lymphoma cells, MLN8237 and cyclophosphamide showed syn- ergistic effects. Mice bearing lymphoma xenograft had rapid disease progression with median survival of ~ 35 days when treated with cyclophosphamide alone. In contrast, the combination of cyclophosphamide and MLN8237 induced complete tumor regression in all mice, which led to improvement in survival compared with the single agent
Targeted Oncology – Springer Journals
Published: Aug 19, 2019
Access the full text.
Sign up today, get DeepDyve free for 14 days.